Travere Therapeutics, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 21, 2026, disclosing a planned CEO succession and the terms of a transition agreement with its departing chief executive.

Key Highlights

  • CEO departure date: Eric Dube, Ph.D. will step down as President, Chief Executive Officer, and Board member effective December 1, 2026.
  • Successor named: Bradley L. Campbell, age 51, has been appointed President and Chief Executive Officer, also effective December 1, 2026.
  • Campbell's prior role: He served as President and CEO of Amicus Therapeutics, Inc. from August 2022 until its acquisition by BioMarin Pharmaceutical Inc. in April 2026.
  • Dube's transition role: Dr. Dube will continue as an employee in an Executive Advisor capacity through February 15, 2027, and then transition to a consulting role for up to 18 months following December 1, 2026.
  • Equity treatment: Dr. Dube's previously granted stock awards will continue to vest during the Transition Period, but performance-based restricted stock units will cease vesting at the Employment Termination Date and any unvested portion will be forfeited and cancelled without consideration.
  • COBRA coverage: Contingent on execution of a release of claims, the company will pay Dr. Dube's COBRA premiums for up to 18 months following December 1, 2026, subject to earlier termination conditions.

Travere Therapeutics CEO Succession: Dube Departure and Campbell Appointment Details

According to the filing, Travere Therapeutics (NASDAQ:TVTX) and Dr. Eric Dube "mutually agreed to the timeline and terms surrounding the planned transition" on September 21, 2026. Dr. Dube will remain in his current role, receiving his current base salary, until the Officer Resignation Date of December 1, 2026. He will also remain eligible for his annual cash incentive bonus for 2026, as determined by the Board of Directors and/or the Compensation Committee, but will not be eligible to participate in the company's cash incentive bonus program for 2027, the filing stated.

Bradley L. Campbell's background, as described in the filing, includes over 25 years in the biopharmaceutical industry. Before leading Amicus Therapeutics as President and CEO, he served as its President and Chief Operating Officer from January 2015. He previously held roles at Genzyme Corporation and Bristol-Myers Squibb, and worked as a strategy consultant for Marakon Associates. He holds a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School. The filing states there are no arrangements beyond those disclosed pursuant to which Mr. Campbell was selected, and no related party transactions requiring disclosure.

The filing further disclosed that if the company terminates Dr. Dube's consulting engagement for convenience, vesting of his then-outstanding equity awards will accelerate to equal the amount that would have vested over 18 continuous months from the termination date. If such termination occurs within three months prior to, or within twelve months after, a Change in Control as defined in the Transition Agreement, all outstanding equity awards will accelerate in full. The full text of the Transition Agreement is attached as Exhibit 10.1 to the filing.

What Was Disclosed

Travere Therapeutics disclosed a CEO transition effective December 1, 2026, naming Bradley L. Campbell as successor to Eric Dube, Ph.D., and filed the terms of a Transition and Separation Agreement governing Dr. Dube's compensation, equity vesting, consulting arrangement, and COBRA coverage through the transition period.